The FDA’s alert does not prevent Hims Hers Health from continuing to sell the treatment, but it raises questions about the future of these products in the market. The agency has stressed that ...

In its first quarter 2025 investor letter, ClearBridge Small Cap Growth Strategy emphasized stocks such as Hims & Hers Health, Inc. (NYSE:HIMS). Hims & Hers Health, Inc. (NYSE:HIMS) offers a ...

Nasal spray H5N1 avian influenza vaccine developed Date: April 8, 2025 Source: The University of Hong Kong Summary: Scientists have pioneered an influenza virus vector-based nasal spray vaccine ...

No matter the culprit, Hims can help ... There are other unique options, including a spray that contains both minoxidil and finasteride to boost growth. It's an easy option for people who don ...

American depository receipts of Novo Nordisk slide 1.4%, to $61.68, and shares of Hims & Hers edge 1.2% lower, to $25.68. Maxeon Solar Technologies said it is establishing an alternative network ...

Hims is a telehealth platform for men that offers virtual care for various health concerns. The platform addresses issues such as hair loss, sexual health, weight management, skincare and mental ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed. Shares of the digital healthcare platform ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug. Hours after Hims & Hers posted a blog ...

Hims & Hers Health shares rose 5% Tuesday after announcing it will offer Eli Lilly’s Zepbound and Mounjaro through its weight loss platform, according to CNBC.

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...